• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    QualTek Names New Independent Board Appointees to its Board of Directors

    3/7/22 7:57:00 AM ET
    $QTEK
    $VBIV
    Telecommunications Equipment
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QTEK alert in real time by email

    BLUE BELL, Pa., March 7, 2022 /PRNewswire/ -- QualTek Services Inc. ("QualTek" or the "Company") (NASDAQ:QTEK), a leading turnkey provider of infrastructure services to the North American 5G wireless, telecom, power grid modernization and renewable energy sectors, announced today the appointment of Daniel Lafond, who joined the board as an independent director on March 2, 2022. QualTek previously appointed Jigisha Desai and Sam Chawla as independent board members.  

    (PRNewsfoto/QualTek USA, LLC)

    "We are pleased to have Jigisha, Sam and Dan as independent directors to QualTek's board during this exciting time for the company," said QualTek CEO Scott Hisey. "QualTek will benefit from their strong voices and experience growing and transforming public companies. Now that we've entered the public markets, QualTek is focused on executing on our growing backlog and continue providing best-in-class services to our customers, specifically surrounding the buildout of national 5G networks."

    Daniel Lafond joins the Board of Directors with more than 20 years of experience in the telecommunications and technology industries, including in many senior leadership roles at AT&T Inc., Comcast Corporation ("Comcast") and QuadGen Wireless Solutions Inc. Most recently, Mr. Lafond served seven years as Senior Vice President of Sales at Comcast.  In this role, Dan led the transformation strategy for XFINITY sales channels and operations. Mr. Lafond helped drive customer growth by investing in sales channel to better serve the customer, as well as creating a more centralized sales operations function to help support the employee serving the customers of Xfinity. Dan graduated from LaSalle University with a BS in Accounting.

    Jigisha Desai has been a member of the Board of Directors of QualTek since February 2022. Ms. Desai has over 30 years of financial management, business leadership, and corporate strategy experience. She had a 29-year career at Granite Construction Incorporated, including serving as Executive Vice President and Chief Strategy Officer. Additionally, Ms. Desai is a board member of 1st Capital Bank, Tutor Perini Corporation, and Element US. Formerly, she served on the boards of Pacific Collegiate School, Pajaro Valley Health Trust and Girls Inc. Ms. Desai is a member of the Association of Financial Professionals and a Certified Treasury Professional. Ms. Desai received a B.S. in Accounting from the University of Houston, an M.B.A. in Corporate Finance from Golden Gate University, and completed Harvard Business School's Advanced Management Program.

    Sam Chawla has been a member of the Board of Directors of ROCR since April 2021. Mr. Chawla has been a Portfolio Manager of Perceptive Advisors LLC, an investment fund focused on the healthcare sector, since 2013. Previously, Mr. Chawla served as a member of the board of directors of each of VBI Vaccines Inc. (NASDAQ:VBIV), and Great Basin Scientific, Inc. Prior to 2013, Mr. Chawla was a Managing Director in Investment Banking at UBS and held executive positions at Credit Suisse.  Mr. Chawla received an M.B.A. from Georgetown University and a B.A. in Economics from Johns Hopkins University.

    About QualTek

    Founded in 2012, QualTek is a leading technology-driven provider of infrastructure services to the 5G wireless, telecom, power grid modernization and renewable energy sectors across North America. QualTek has a national footprint with more than 80 operation centers across the U.S. and a workforce of over 5,000 people. QualTek has established a nationwide operating network to enable quick responses to customer demands as well as proprietary technology infrastructure for advanced reporting and invoicing. The Company will report within two operating segments: Telecommunications, and Renewables and Recovery and has already become a leader in providing disaster recovery logistics and services for electric utilities. For more information, please visit https://www.qualtekservices.com.

    Forward Looking Statements

    This communication contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, including statements about the anticipated benefits of the Business Combination and the financial condition, results of operations, earnings outlook and prospects of QualTek and may include statements for the period following the consummation of the Business Combination. Forward-looking statements are typically identified by words such as "plan," "believe," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," "could," "may," "might," "possible," "potential," "predict," "should," "would" and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

    The forward-looking statements are based on the current expectations of the management of QualTek and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those discussed and identified in public filings made with the SEC by QualTek.

    Should one or more of the risks or uncertainties materialize or should any of the assumptions made by the management of QualTek prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

    All subsequent written and oral forward-looking statements concerning the Business Combination or other matters addressed in this communication and attributable to QualTek or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this communication. Except to the extent required by applicable law or regulation, QualTek undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of this communication to reflect the occurrence of unanticipated events

    Media Contact:

    QualTek IR/Communications

    Gianna Lucchesi

    [email protected] 

    (484) 804 - 4585

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/qualtek-names-new-independent-board-appointees-to-its-board-of-directors-301496215.html

    SOURCE QualTek Services Inc.

    Get the next $QTEK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $QTEK
    $VBIV

    CompanyDatePrice TargetRatingAnalyst
    VBI Vaccines Inc. New
    $VBIV
    11/11/2022$5.00 → $2.00Strong Buy → Outperform
    Raymond James
    VBI Vaccines Inc. New
    $VBIV
    3/8/2022$9.00 → $6.00Strong Buy
    Raymond James
    VBI Vaccines Inc. New
    $VBIV
    12/29/2021$7.00 → $6.00Buy
    Jefferies
    More analyst ratings

    $QTEK
    $VBIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • VBI Vaccines downgraded by Raymond James with a new price target

      Raymond James downgraded VBI Vaccines from Strong Buy to Outperform and set a new price target of $2.00 from $5.00 previously

      11/11/22 7:30:44 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James reiterated coverage on VBI Vaccines with a new price target

      Raymond James reiterated coverage of VBI Vaccines with a rating of Strong Buy and set a new price target of $6.00 from $9.00 previously

      3/8/22 7:08:44 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on VBI Vaccines with a new price target

      Jefferies resumed coverage of VBI Vaccines with a rating of Buy and set a new price target of $6.00 from $7.00 previously

      12/29/21 7:23:26 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QTEK
    $VBIV
    SEC Filings

    See more
    • VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

      8/2/24 4:05:34 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Other Events

      8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

      7/30/24 10:28:18 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Inc. New filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

      6/25/24 4:15:17 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QTEK
    $VBIV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • VBI Vaccines Provides an Update on its Restructuring Proceedings

      VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided an update on the restructuring proceedings announced on July 30, 2024. U.S. Chapter 15 Filing On August 2, 2024, the United States Bankruptcy Court for the District of Delaware granted provisional relief under Chapter 15 of the U.S. Bankruptcy Code, and scheduled a further hearing to consider the recognition of the July 30, 2024, Ontario Superior Court of Justice (Commercial List) order ("Initial Order"), which granted the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("C

      8/2/24 4:05:00 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

      VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the Ontario Superior Court of Justice (Commercial List) ("Court") has issued an initial order ("Initial Order") granting the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("CCAA"). The Initial Order provides for, among other things: (i) a stay of proceeding in favour of VBI, (ii) approval of the DIP Loan (as described below), and (iii) the appointment of Ernst & Young Inc. ("EY") to serve as monitor ("Monitor") in the Court during the restructuring ("Restructuring Pro

      7/30/24 9:55:00 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Announces Results of Annual General Meeting

      VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 25, 2024 (the "Meeting"). The total number of common shares of the Company ("Common Shares") represented by shareholders ("Shareholders") present in person or represented by proxy at the Meeting was an aggregate of 13,879,327 Common Shares, representing 48.39% of VBI's issued and outstanding Common Shares as of the record date for the Meeting, April 26, 2024. The voting results with respect to each of the following eight dir

      6/25/24 4:15:00 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QTEK
    $VBIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Braga Damian

      4 - VBI Vaccines Inc/BC (0000764195) (Issuer)

      7/31/23 5:00:28 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Dewilde Michel

      4 - VBI Vaccines Inc/BC (0000764195) (Issuer)

      7/31/23 5:00:30 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Beattie Nell

      4 - VBI Vaccines Inc/BC (0000764195) (Issuer)

      7/28/23 6:30:45 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QTEK
    $VBIV
    Leadership Updates

    Live Leadership Updates

    See more
    • Brii Biosciences Provides Latest Clinical Development and Corporate Updates

      Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the

      7/5/23 7:18:00 PM ET
      $ANTX
      $VBIV
      $VIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • VBI Vaccines Appoints Vaughn Himes to Board of Directors

      VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief Technical Officer of Seagen Inc., has joined VBI's Board of Directors. Dr. Himes has a 30+-year successful track record in biotechnology strategic direction and change management, driving value creation and growth at both small and large biopharmaceutical companies. "Vaughn brings extensive CMC (chemistry, manufacturing, and controls), product development, quality, and strategic business transformation expertise to VBI," said Jeff Baxter, VBI's President and CEO. "In his current and previo

      4/25/23 8:00:00 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

      VBI will continue to heavily prioritize making a difference in both prevention and treatment of hepatitis B (HBV) with PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and immunotherapeutic candidate VBI-2601 Cost-saving measures expected to reduce quarterly operating expenses and headcount by 30-35% VBI to effect a 1-for-30 reverse stock split of its issued and outstanding common shares – shares are expected to trade on the new split-adjusted basis as of commencement of trading on April 12, 2023 VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced plans to focus the C

      4/4/23 8:00:00 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QTEK
    $VBIV
    Financials

    Live finance-specific insights

    See more
    • Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

      Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie

      3/22/24 7:00:00 AM ET
      $ANTX
      $VBIV
      $VIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • VBI Vaccines Reports Third Quarter 2023 Financial Results

      PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023 Continued execution across earlier-stage pipeline, including: Initiation of Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) patients Interim Phase 1 data announced for pan-coronavirus candidate, VBI-2901 Novel mRNA-launched eVLP platform technology announced VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023. "In Q3, we were focused on pip

      11/14/23 4:05:00 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

      First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong intrinsic anti-HBsAg responses for curative treatments to start before the end of 2023 Regulatory submissions and preparation for launches of PreHevbri® in APAC countries and regions are underway Near-term revenue opportunities with PreHevbri® and strong balance sheet supporting operations through 2026 Company to host earnings call on August 22 at 8:00 PM ET / August 23 at 8:00 AM HKT and an HBV R&D Day on August 24 from 1:00-2:30 PM HKT DURHAM, N.C. and BEIJING, Aug. 22, 2023 /

      8/22/23 10:00:00 AM ET
      $VBIV
      $VIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $QTEK
    $VBIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by VBI Vaccines Inc. New (Amendment)

      SC 13D/A - VBI Vaccines Inc/BC (0000764195) (Subject)

      4/17/24 4:16:49 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by VBI Vaccines Inc. New (Amendment)

      SC 13D/A - VBI Vaccines Inc/BC (0000764195) (Subject)

      11/17/23 6:59:27 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by VBI Vaccines Inc. New

      SC 13G - VBI Vaccines Inc/BC (0000764195) (Subject)

      7/20/23 4:16:39 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care